Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Candida infections represent a major threat in neonatal intensive care units. This is the first prospective study to obtain caspofungin plasma levels and safety data for neonates and very young infants. Patients of <3 months of age receiving intravenous amphotericin B for documented or highly suspected candidiasis were enrolled in a single-dose (n= 6) or subsequent multiple-dose (n= 12) panel; all received caspofungin at 25 mg/m 2 once daily as a 1-hour infusion. Caspofungin plasma levels were measured by high-performance liquid chromatography and compared to historical data from adults. Patient chronological ages ranged from 1 to 11 weeks, and weights ranged from 0.68 to 3.8 kg. Gestational ages ranged from 24 to 41 weeks. Geometric mean (GM) peak (C1 h) and trough (C24 h) caspofungin levels were 8.2 and 1.8 μg/ml, respectively, on day 1, and 11.1 and 2.4 μg/ml, respectively, on day 4. GM ratios for C1 h and C24 h for neonates/infants relative to adults receiving caspofungin at 50 mg/day were 1.07 and 1.36, respectively, on day 1, and 1.18 and 1.21, respectively, on day 4. Clinical and laboratory adverse events occurred in 17 (94%) and 8 (44%) patients, respectively. Five patients (28%) had serious adverse events, none of which were considered drug related. Caspofungin at 25 mg/m 2 once daily was well tolerated in this group of neonates/infants of <3 months of age and appears to provide relatively similar plasma exposure to that obtained in adults receiving 50 mg/day. However, the small number of patients studied precludes any definitive recommendations about caspofungin dosing for this group comprising a broad range of ages and weights.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationArathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254 · cited 1×
“Caspofungin is an echinocandin antifungal that is effective as primary therapy for esophageal candidiasis (1, 6, 19), candidemia (8), and other invasive Candida infections (5) in adults.”
BackgroundCandidal Meningitis in Neonates: A 10-Year Review
Fernandez, M., Moylett, E. H., Noyola, D. E., & Baker, C. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313973 · Cited by 163 · cited 1×
“Central nervous system involvement is of particular concern in neonates and premature infants with disseminated candidiasis (2, 7).”
Background
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360
“Caspofungin 25 mg/m(2)/day (C-II) Relatively limited PK and dosing designed to approximate drug exposure in adults, rather than HCME Evidence for efficacy [62–64] Pharmacokinetics in neonates: [61]”
BackgroundMethodEchinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
Metadata
- Authors
- Sáez-Llorens, X., Macias, M., Maiya, P., Pineros, J., Jafri, H. S., Chatterjee, A., Ruiz, G., Raghavan, J., Bradshaw, S. K., Kartsonis, N. A., Sun, P., Strohmaier, K. M., Fallon, M., Bi, S., Stone, J. A., & Chow, J. W.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-03
- Volume
- 53
- Issue
- 3
- Pages
- 869-875
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2145760158
- Cited by
- 137
- References
- 4
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age. https://app.cochat.ai/papers/10.1128/aac.00868-08
- The paper
- Sáez-Llorens, X., Macias, M., Maiya, P., Pineros, J., Jafri, H. S., Chatterjee, A., Ruiz, G., Raghavan, J., Bradshaw, S. K., Kartsonis, N. A., Sun, P., Strohmaier, K. M., Fallon, M., Bi, S., Stone, J. A., & Chow, J. W. (2009). Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00868-08
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.